Pembrolizumab,Axitinib,Sunitinib
Merck,Pfizer
['pembro', 'kcsm,(-skcsm)', 'rcc,(-irccs),(-srcc),(-urcc)', 'axitinib']
frontline pembrolizumab plus axitinib continues to show benefits in advanced ccrcc at 5-year follow-up #oncology #nursing #immunotherapy #rcc #kcsm #asco23 
Capturing the voice of nursing professionals in the oncology news landscape.